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Improved understanding of the current burden of hypertension, including awareness, 
treatment, and control, is needed to guide relevant preventative measures in Nigeria. 
A systematic search of studies on the epidemiology of hypertension in Nigeria, pub-
lished on or after January 1990, was conducted. The authors employed random- 
effects meta- analysis on extracted crude hypertension prevalence, and awareness, 
treatment, and control rates. Using a meta- regression model, overall hypertension 
cases in Nigeria in 1995 and 2020 were estimated. Fifty- three studies (n = 78 949) 
met our selection criteria. Estimated crude prevalence of pre- hypertension 
(120- 139/80- 89 mmHg) in Nigeria was 30.9% (95% confidence interval [CI]: 22.0%- 
39.7%), and the crude prevalence of hypertension (≥140/90 mmHg) was 30.6% (95% 
CI: 27.3%- 34.0%). When adjusted for age, study period, and sample, absolute cases 
of hypertension increased by 540% among individuals aged ≥20 years from approxi-
mately 4.3 million individuals in 1995 (age- adjusted prevalence 8.6%, 95% CI: 6.5- 
10.7) to 27.5 million individuals with hypertension in 2020 (age- adjusted prevalence 
32.5%, 95% CI: 29.8- 35.3). The age- adjusted prevalence was only significantly higher 
among men in 1995, with the gap between both sexes considerably narrowed in 2020. 
Only 29.0% of cases (95% CI: 19.7- 38.3) were aware of their hypertension, 12.0% 
(95% CI: 2.7- 21.2) were on treatment, and 2.8% (95% CI: 0.1- 5.7) had at- goal blood 
pressure in 2020. Our study suggests that hypertension prevalence has substantially 
increased in Nigeria over the last two decades. Although more persons are aware 
of their hypertension status, clinical treatment and control rates, however, remain 
low. These estimates are relevant for clinical care, population, and policy response in 
Nigeria and across Africa.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction 
in any medium, provided the original work is properly cited and is not used for commercial purposes.
© 2021 The Authors. The Journal of Clinical Hypertension published by Wiley Periodicals LLC.
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1  |  INTRODUC TION
Hypertension (HTN) is a leading risk factor for cardiovascular disease 
(CVD) worldwide.1,2 Low- and middle- income countries (LMICs), in-
cluding Nigeria, appear to be worst hit, with relatively higher number 
of cases and limited awareness, treatment, and control rates, against 
the trend observed in developed countries.3,4
In Nigeria, HTN is the most frequently diagnosed CVD risk equiv-
alent, with HTN- related complications accounting for approximately 
a quarter of emergency admissions in urban hospitals.5,6 The Nigerian 
population's mean blood pressure is higher than that of populations in 
Europe and the United States.7 In prior work,8 we reported that one 
in four adult Nigerians is hypertensive and that HTN unawareness is 
a likely contributor to deaths from CVD in the country.8,9
Though numerous prior studies have provided estimates on the 
prevalence of HTN in Nigeria,7,9- 11 few studies have examined HTN 
trends over time. These data may be particularly informative in light 
of the substantial and more recent demographic shifts occurring in 
the Nigerian population.3
The goal of this systematic review was to estimate both the prev-
alence of pre- HTN and HTN in Nigeria, and the level of awareness, 
treatment, and control of HTN. Further, we sought to examine for 
evidence of geographic, urban/rural, and sex- based differences in 
these estimates. These data are required to understand the likely 
trajectory of HTN in the country (useful for regional and global com-
parisons) and guide relevant country- wide strategies to address the 
burden of HTN- related disease.
2  |  METHODS
2.1  |  Search strategy
We conducted a systematic search of four databases— MEDLINE, 
EMBASE, Global Health, and Africa Journals Online (AJOL)— for 
studies on the prevalence of HTN in Nigeria. We also searched 
for studies on cardio- metabolic risk as we identified from an initial 
scoping exercise that a high proportion of such studies report on the 
prevalence of HTN (search terms are shown in Table 1). Unpublished 
(gray) documents were mainly sourced from Google Scholar and 
Google searches. Titles and abstracts of studies were reviewed, and 
full texts of relevant studies were accessed for further screening. 
The reference lists of accessed full texts were hand- searched for ad-
ditional studies. Authors of selected papers were contacted for any 
missing information.
2.2  |  Selection criteria
Studies were selected if they were (i) original population (or 
community)- based studies reporting on the prevalence of HTN in 
Nigeria, (ii) published on or after January 1, 1990, (iii) conducted 
among individuals aged at least 15 years, and (iv) providing estimates 
on the prevalence, awareness, control, or treatment of HTN in 
Nigeria. We excluded hospital- based reports, studies on Nigerians in 
diaspora, reviews, viewpoints, and commentaries.
2.3  |  Case definitions
The main outcome measures in this study were (i) prevalence of pre- 
HTN, (ii) prevalence of HTN, (iii) awareness of HTN (expressed as 
percent of HTN cases aware of their status, (iv) treatment of HTN 
(expressed as percent of HTN cases on antihypertensive medication), 
and (v) control of HTN (expressed as percent of HTN cases with blood 
pressure controlled). The American College of Cardiology (ACC) and 
American Heart Association (AHA) recently published an updated 
report on the prevention, detection, evaluation, and management of 
HTN in adults.12 In this report, stage 1 HTN was defined as a systolic 
blood pressure (SBP) of 130- 139 mmHg or a diastolic blood pressure 
(DBP) of 80- 89 mmHg, and stage 2 as SBP of 140 mmHg or more 
or a DBP of 90 mmHg or more. However, as this classification has 
not been employed by several epidemiologic studies in Nigeria, we 
maintained the definition of HTN by the Joint National Committee 
on prevention, detection, evaluation, and treatment of high blood 
pressure.13,14 Therefore, we defined HTN as SBP of 140 mmHg or 
more, a DBP of 90 mmHg or more, taking antihypertensive medica-
tion, or having been diagnosed as hypertensive by a physician (corre-
sponding to stage 2 HTN in the 2017 ACC/AHA classification). When 
available, we also extracted the prevalence of pre- HTN (defined as 
SBP of 120- 139 mmHg or a DBP of 80- 89 mmHg). For the awareness 
of HTN, we defined this as self- reported prior diagnosis of HTN by 
a doctor or a certified health worker, excluding women who were 
diagnosed with HTN during pregnancy.15 We defined treatment of 
TA B L E  1  Search terms on hypertension in Nigeria
No. Searches
1 africa/ or africa, sub- sahara/ or africa, western/ or nigeria/
2 exp vital statistics/
3 (incidence* or prevalence* or morbidity or mortality).tw.
4 (disease adj3 burden).tw.
5 exp “cost of illness”/
6 case fatality rate.tw
7 hospital admissions.tw
8 Disability adjusted life years.mp.
9 (initial adj2 burden).tw.
10 exp risk factors/
11 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10
12 exp hypertension/ or high blood pressure/ or hypertensive 
heart disease/ or cardiovascular risks/ or cardio- 
metabolic risks
13 1 and 11 and 12
14 Limit 13 to “1990- current”
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HTN as self- reported medication use to lower blood pressure at 
the time of interview.15 Control of HTN was defined as SBP below 
140 mmHg and DBP below 90 mmHg while currently on antihyper-
tensive medication.15
2.4  |  Data extraction
Literature searches and assessment of eligible studies were con-
ducted independently by three reviewers (DA, EOO, and AA), accord-
ing to the selection criteria to ensure consistency in final selection of 
studies. Disagreements in study selection were resolved by consen-
sus. Data on the study site, period, design, setting (urban or rural), 
sample size, and mean age of the population were extracted. These 
were matched with corresponding data on the number of HTN cases 
and prevalence of HTN in each study.
2.5  |  Quality assessment
We adapted a previously used quality assessment criteria for stud-
ies on chronic diseases16 to provide insights on the quality of se-
lected studies. We screened for explicit description of methods, 
protocols, case ascertainment, and sampling and representative-
ness of reported estimates within the larger geopolitical zone. We 
graded studies as high (4- 5), moderate (2- 3), or low quality (0- 1) (see 
Supplemental Material for details of quality grading).
2.6  |  Data analysis
We conducted a random- effects meta- analysis, using the 
DerSimonian and Laird Method,17 on the individual study es-
timates to generate national and subnational pooled crude esti-
mates of the respective study outcomes in Nigeria. Standard errors 
were determined from the reported crude estimates and popula-
tion denominators, assuming a binominal (or Poisson) distribution. 
We assessed heterogeneity between studies using I- squared (I2) 
statistics. Subgroup analysis was conducted to detect causes of 
heterogeneity. We investigated publication bias using the Funnel 
plot and Egger's test. As described in previous studies,8,16 we 
constructed a meta- regression epidemiologic model accounting 
for study sample, year, and mean age to determine age- adjusted 
prevalence distribution of HTN by age of the Nigerian population. 
Model expressed as:
where PrevHTN(%) is the prevalence of hypertension in percentage, α is 
the constant, β1 and β2 are regression coefficients for mean age and 
study year, and ui represents study- level variance.
From this model and the age- adjusted prevalence rates, we 
estimated the absolute number of adult individuals with HTN in 
Nigeria at midpoints of the United Nation (UN) population 5- year 
age groups for Nigeria for the years 1995 and 2020.18 All statis-
tical analyses were conducted on STATA (Stata Corp V.14, Texas, 
USA). The study was conducted in line with the PRISMA (Preferred 
Reporting Items for Systematic Reviews and Meta- Analyses) guide-
lines.19 The complete dataset employed in this review is available 
in the Supplemental Material. Further details on searches, data 
extraction, and analysis are available on reasonable request from 
corresponding author.
3  |  RESULTS
3.1  |  Search results
Our searches returned 4154 studies— 4132 from the four databases 
(MEDLINE, 1691; EMBASE, 2123; Global Health, 246; and AJOL, 
72), and an additional 22 studies identified from Google Scholar, 
Google searches, and reference lists of relevant studies. After dupli-
cates were removed, 1897 titles were screened for relevance (ie, for 
evidence of a population- based study on HTN in Nigeria). On apply-
ing the selection criteria, 1709 studies were excluded. We assessed 
188 full texts, which were screened explicitly using the selection 
and quality criteria. Fifty- three studies were finally selected for both 
qualitative and quantitative syntheses (Figure 1).
3.2  |  Study characteristics
The 53 studies were selected across the six geopolitical zones 
of Nigeria and covering a total population of 78 949 individuals 
(Table 2). The South- west and South- east were represented by 
15 studies each, followed by the South- south with 14 studies. 
North- central had three studies, North- west, three; and North- 
east, two. One study was conducted across multiple sites in the 
country. Twenty- one studies each were conducted in urban and 
rural settings, with 13 in mixed urban- rural settings. We rated 
32 studies as high quality, and the remaining 21 rated as moder-
ate quality. Study periods ranged from 1995 to 2017, with most 
studies (90%) were conducted within a one- year period. Sample 
mean age ranged from 23.0 to 71.1 years. Heterogeneity was high 
across studies, with I- squared (I2) estimated at 99.1% (P < .001). 
The Funnel plot suggests no publication bias, with the Egger's test 
(P = .309) further confirming no small study effects (Supplemental 
Material).
3.3  |  Prevalence of pre- HTN in Nigeria
The prevalence of pre- HTN (SBP 120- 139 mmHg or DBP 80- 
89 mmHg) reported in studies ranged from 17.2% estimated from 
two cities in the South- south in 2012,20 to 42.5% recorded in 
Anambra State, South- east Nigeria, in 2016.21 The estimated pooled 
PrevHTN(%) =  + 1 ∗ Meanage + 2 ∗ Studyyear + ui
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crude prevalence of pre- HTN in Nigeria was 30.9% (95% CI: 22.0- 
39.7) (Figure 2). No sex- specific estimates were reported.
3.4  |  Crude prevalence of HTN in Nigeria
From individual study estimates, the highest prevalence of HTN 
(SBP ≥ 140 mmHg or DBP ≥ 90 mmHg) was recorded in an urban 
community in Kaduna State, North- west Nigeria, at 55.9% in 
2018,22 with the lowest prevalence estimated in Ibadan Oyo 
State, South- west Nigeria, at 9.3% in 1999.23 When pooled crude 
prevalence of HTN across the geopolitical zones was considered, 
pooled estimates in the four zones were relatively similar and 
above 30%. The highest prevalence was in the South- east at 
33.3% (95% CI: 27.3- 39.4), closely followed by the North- central 
with a prevalence of 32.2% (95% CI: 13.5- 34.0); while the North- 
west had 31.9% (95% CI: 14.9- 48.9), and the South- west had 
30.2% (95% CI: 23.6- 36.8) (Figure 3). The North- east and the 
South- south had a pooled HTN prevalence of 24.7% (95% CI: 
22.4- 27.1) and 27.6% (95% CI: 21.4- 33.9), respectively. The over-
all pooled crude prevalence of HTN in Nigeria was 30.6% (95% 
CI: 27.3- 34.0) (Figure 3). Although no significant difference, the 
prevalence was slightly higher among women (30.4%, 95% CI: 
25.2- 35.6) than among men (29.5%, 95% CI: 25.4- 33.6) (Table 3 
and Supplemental Material). Across both sexes, the pooled prev-
alence was consistently higher among urban dwellers (33.5%, 
95% CI: 25.1- 42.0) than among rural dwellers (25.5%, 95% CI: 
21.1- 29.9) (Table 3).
3.5  |  Pooled mean SBP and DBP in Nigeria
The pooled mean population SBP in Nigeria was 130.9 mmHg (128.4- 
133.4) and the pooled mean DBP was 81 mmHg (79.5- 82.8) (Table 3 
and Supplemental Material).
3.6  |  Awareness, treatment, and control of HTN 
in Nigeria
The pooled HTN awareness rate (expressed as a percentage of all 
HTN cases) was 29.0% (95% CI: 19.7- 38.3), while 12.0% (95% CI: 
F I G U R E  1  Flowchart of selection of 
studies
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2.7- 21.2) were on antihypertensive medications, and 2.8% (95% CI: 
0.1- 5.7) of these had at- goal blood pressure (Figure 4).
3.7  |  Estimated number of individuals with HTN 
in Nigeria
The meta- regression epidemiologic modeling showed that age 
and study period were statistically significant determinants of 
HTN prevalence in Nigeria, P < .001 (Supplemental Material). The 
prevalence of HTN increased significantly with advancing age and 
year of study. For example, in 1995, the prevalence of HTN at ages 
20- 24 and 50- 59 years was 1.0% and 15.6%, respectively, and by 
2020, the prevalence rates at these age brackets had increased to 
23.5% and 40.0%, respectively (Table 4). Using the United Nations 
demographic projections for Nigeria, we estimated that approxi-
mately 4.3 million individuals over the age of 19 had HTN in Nigeria 
in 1995 (age- adjusted prevalence of 8.6%, 95% CI: 6.5- 10.7). This 
figure increased by 540% to 27.5 million individuals over the age 
of 19 with HTN in 2020 (age- adjusted prevalence of 32.5%, 95% 
CI: 29.8- 35.3) (Table 4). When the sexes were considered, cases 
increased significantly from 3 million (12.0%, 95% CI: 9.3- 14.8) to 
14.2 million (33.5%, 95% CI: 29.3- 37.7) among men, and 1.3 mil-
lion (5.2%, 95% CI: 2.5- 7.9) to 13.2 million (31.5%, 95% CI: 27.0- 
35.9) among women between 1995 and 2020, respectively. The 
age- adjusted prevalence was only significantly higher in men in 
1995, with the gap in prevalence between both sexes considerably 
narrowed in 2020.
4  |  DISCUSSION
In this systematic review of 53 studies on the prevalence of HTN in 
Nigeria, we found strong evidence that HTN has become far more 
common among Nigerian adults in recent years and that aware-
ness of the condition remains alarmingly low. We also provide the 
first country- specific estimates of pre- HTN for Nigeria, and pre-
sent strong evidence of geographic heterogeneity in this condition. 
These results have strong implications for future preventative and 
educational campaigns.
Our results suggest that between 1995 and 2020, HTN cases in 
Nigeria increased by over 540% from four million individuals to 28 
million individuals. We estimated that the age- adjusted HTN prev-
alence in 2020 was 32.5%, a substantially higher number than the 
28.0% prevalence we estimated in 2010 in a prior study.8 Likely con-
tributors to this high and steady increase in HTN include population 
aging, increased urbanization, unhealthy lifestyles, and the absence 
of effective nation- wide preventative measures. Our results lend 
credence to concerns that HTN and related complications may soon 
represent the most significant public health and economic threat in 
many African countries, overshadowing epidemics such as malaria 
and other infectious diseases.7,24,25
F I G U R E  2  Crude prevalence of pre- hypertension in Nigeria
8  |    ADELOYE Et AL.
F I G U R E  3  Crude prevalence of hypertension in Nigeria
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Given our pooled mean SBP and DBP estimates of 131 mmHg 
and 81 mmHg, respectively, our study findings may indicate that 
many Nigerians are also in the pre- hypertensive stage. Though 
pre- HTN does not connote inevitable progression to HTN, stud-
ies had long shown that the presence of pre- HTN increases the 
risk for HTN, cardiovascular complications, and target organ 
damage by 30% in the absence of lifestyle modifications or treat-
ment.26- 28 We estimated that nearly one in three Nigerians is pre- 
hypertensive. Our estimate is in the range of pre- HTN prevalence 
estimates from Ghana (30.7%) and South Africa (29.4%), but higher 
than the pooled estimate in four sub- Saharan African countries 
that included Nigeria (21.0%).29,30 In contrast, Chow et al31 esti-
mated that pre- HTN prevalence was 36.8% from a multicountry 
study, although this does not include Nigeria. Comparison be-
tween prior studies and ours may be challenging due to the dif-
ferences in the methodology between studies. However, several 
studies29- 31 including the current have pointed to a high preva-
lence of pre- HTN and HTN in Nigeria and neighboring countries, 
calling for more awareness and education.
We found evidence of substantial regional variation in the prev-
alence of HTN in Nigeria, which ranged from 25% to 33% across 
the geopolitical zones. The highest prevalence was in the South- east 
and North- central at 33.3% and 32.2%, respectively. Although the 
regional pattern of distribution may be subject to further studies, 
Murthy et al32 reported high prevalence of HTN in 2013 among the 
Nupe and Igbo communities in the North- central and South- east at 
50.5% and 40.4%, respectively. Dietary differences in these regions, 
particularly in the amount of oil and salt used in food, may be the 
contributing factor. The significant variations in socio- economic 
conditions also have important implications on dietary choices, par-
ticularly in urban settings characterized by high consumption of pro-
cessed foods, without population- wide strategies promoting healthy 
diets.33,34 Moreover, varying weather and climatic conditions in 
Nigeria considerably affect farming and the type of food crops pro-
duced, possibly another important factor for the dietary differences. 
Our findings of a higher prevalence of HTN among urban dwellers 
and those of advanced age are consistent with findings from numer-
ous previous studies.25,35- 37
Our estimates clearly indicate a narrowing prevalence gap 
between men and women, with a difference of 7% in 1995 and 
2% in 2020. In prior work,8 we reported a 5% difference between 
the two sexes (30% men vs 25% women) in 2010. Although the 
current crude prevalence difference in both sexes was not statis-
tically significant, this was slightly higher among women (30.4%) 
compared with men (29.5%). These findings are consistent with 
those from a 2013 study of 13 504 Nigerians, in which the prev-
alence of HTN was higher among women (46.8%) than among 
men (42.6%). The rising prevalence of HTN among women could 
be linked to increasing obesity, decreasing physical inactivity and 
unhealthy diets.38- 41 Moreover, women appear to suffer worse 
TA B L E  3  Pooled crude estimates of prevalence of hypertension in Nigeria
Region
Both sexes Men Women
Prevalence % (95% 
CI) I2, P- value
Prevalence % (95% 
CI) I2, P- value
Prevalence % (95% 
CI) I2, P- value
Nation- wide
Hypertension 30.6 (27.3- 34.0) 99.1, <.001 29.5 (25.4- 33.6) 98.2, <.001 30.4 (25.2- 35.6) 99.2, <.001
Pre- hypertension 30.9 (22.0- 39.6) 99.3, <.001 - - - - 
Awarenessa  29.0 (19.7- 38.3) 98.9, <.001 - - - - 
Treatmenta  12.0 (2.7- 21.2) 97.9, <.001 - - - - 
Controla  2.8 (0.0- 5.7) 83.1, .015 - - - - 
SBP (mmHg) 130.9 (128.4- 133.4) 90.7, <.001 - - - - 
DBP (mmHg) 81.1 (79.5- 82.8) 95.0, <.001 - - - - 
Geopolitical zone
North- central 32.2 (13.5- 34.0) 99.1, <.001 35.9 (21.6- 50.2) 93.3, <.001 24.8 (21.3- 28.4) 97.1, <.001
North- east 24.7(22.4- 27.1) 0.0, .457 23.3 (19.5- 27.1) 28.7. .236 24.8 (21.3- 28.4) 0.0, .867
North- west 31.9 (14.9- 48.9) 97.7, <.001 20.1 (7.2- 33.1) 90.9, <.001 34.0 (13.9- 54.1) 97.2, <.001
South- east 33.3 (27.3- 39.4) 99.0, <.001 40.8 (33.7- 48.0) 95.1, <.001 35.8 (29.0- 42.6) 96.1, <.001
South- south 27.6 (21.4- 33.9) 98.3, <.001 24.4 (18.9- 29.8) 92.2, <.001 20.9 (15.6- 26.3) 94.6, <.001
South- west 30.2 (23.6- 36.8) 99.2, <.001 27.3 (17.3- 37.2) 98.0, <.001 30.9 (20.0- 41.8) 99.4, <.001
Settings
Urban 33.6 (25.1- 42.0) 98.8, <.001 27.2 (17.3- 37.2) 97.9, <.001 34.5 (23.2- 45.8) 98.3, <.001
Rural 25.5 (21.1- 29.9) 98.6, <.001 26.4 (20.6- 32.2) 94.5, <.001 22.9 (17.8- 28.1) 95.5, <.001
Mixed 33.7 (26.7- 40.7) 99.3, <.001 35.8 (27.8- 43.7) 98.6, <.001 34.1 (25.0- 43.1) 99.1, <.001
aAwareness, treatment, and control rates expressed as percent of HTN cases. 
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mental, psychological, and emotional consequences from increas-
ing security challenges in Nigeria, with repeated anxiety and panic 
attacks likely having adverse effects on the overall cardiovascu-
lar health of many. In addition, it is worth noting that women are 
more likely to participate in community medical outreach efforts, 
possibly leading to selection bias and relatively higher prevalence 
reported for females.8,9
Compared with our previous pooled awareness rate (17.4%),8 
HTN status awareness (expressed as a percentage of HTN cases in 
the country) increased to 29%. This rate is higher than recorded in 
some African countries (Gabon, Uganda, and Kenya), which ranged 
from 9% to 12%.7,42 Despite the improvement in awareness of HTN 
in the country, the treatment and control rates of HTN (also ex-
pressed as percentage of HTN cases) were relatively low at 12% and 
3%, respectively. These rates are very low compared with treatment 
and control rates in other African countries such as Zimbabwe and 
South Africa, which are above 30%.40,41,43 Addressing the relatively 
low awareness, treatment, and control rates of HTN in Nigeria is key 
to reducing cardiovascular health burden. However, an important 
consideration are the challenges relating to acquiring and adhering 
to antihypertensive medications.9,44 Although cardiology training 
program for medical doctors has relatively improved over the years, 
and there are ongoing studies and trials on medications, several doc-
tors particularly in primary and secondary health facilities lack the 
requisite knowledge of the standard management for hypertension. 
Prescriptions are often too complex, and there is a lack of follow- up 
of cases, resulting in both poor adherence and suboptimal control 
of HTN.33,45
Targeted community- wide programs, commonly organized 
by non- governmental organizations and research groups, are an 
important avenue for blood pressure screening in Nigeria.7,9- 11 
The government, ministry of health and other stakeholders can 
collaborate with these organizations and groups in observing the 
annual May Measurement Month (MMM) across primary care lev-
els in the country to raise awareness and facilitate blood pressure 
screening in catchment communities. According to Beaney et al,46 
the MMM is an inexpensive intervention that can be employed to 
address a shortfall in screening of blood pressures across world 
regions, with over 35 000 (28%) newly diagnosed cases reported 
in sub- Saharan Africa alone in 2017. In addition to initiatives and 
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campaigns such as the MMM, primary health workers who are in 
regular contact with patients can play active roles in promoting 
screening and regular assessment of blood pressure for early iden-
tification of individuals at risk and timely provision of treatments 
where necessary.
Our study should be considered with respect to its limitations. 
Heterogeneity across studies was high, reflecting variations in 
population structures, blood pressure measurement protocols, 
and overall study designs. Of the 53 studies retained, only eight 
were conducted in the Northern regions, and data on age- and 
sex- specific prevalence, and specific geographic settings, were 
not always provided. It is not so clear why studies are predomi-
nantly lower in the North, but this has been observed in previous 
studies,8,16 possibly a reflection of the overall research capacity 
in the region. These factors resulted in some discrepancies in the 
crude sex estimates, although this was accounted for in the final 
model. Moreover, our estimates were based on JNC classifications, 
as there were no available studies based on the 2017 ACC/AHA 
guidelines. Moreover, we reported relatively high age- adjusted 
estimates in the younger age groups in 2020; this should be cau-
tiously interpreted due to sparse overall data for persons under 
30 years. Largely, these limitations are balanced by the strengths 
of our study, including its large sample size, rigorous methodology, 
and its provision of the first nation- wide estimates of the treat-
ment and control of HTN in Nigeria.
5  |  CONCLUSIONS
In summary, the burden of HTN is increasing in Nigeria and our data 
suggest that many Nigerians are pre- hypertensive. HTN prevalence 
appears to be increasing at a faster rate among Nigerian women than 
among men. Further, though the awareness of HTN has improved 
over time, more than half of hypertensive individuals in Nigeria are 
untreated and/or have poorly controlled blood pressure. Our results 
strongly support a need for improved and comprehensive nation- 
wide population preventive strategies to mitigate the effects of HTN 
in Nigeria.
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